FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage

Tools
Purchase
Date Published:
29-Sep-08
Price:
$15,200
Source:
Datamonitor

Introduction

The antidyslipidemic market is expected to fall to $20 billion in 2017. The decline will be driven by the deep genericization of the market, further exacerbated by the patent expiries of the top antidyslipidemic, Pfizer's Lipitor, as well as by the recent negative messages from the ILLUMINATE and ENHANCE clinical trials.

Reasons to Purchase

*Quantify the future size and understand the background of the antidyslipidemic market

*Understand the commercial landscape in terms of new product potential

*Understand the barriers to uptake for novel antidyslipidemics.

 

Purchase